Market capitalization | $3.06b |
Enterprise Value | $2.36b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 197.27 |
P/S ratio (TTM) P/S ratio | 255.78 |
P/B ratio (TTM) P/B ratio | 2.96 |
Revenue growth (TTM) Revenue growth | -73.51% |
Revenue (TTM) Revenue | $11.96m |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
13 Analysts have issued a IDEAYA Biosciences Inc forecast:
13 Analysts have issued a IDEAYA Biosciences Inc forecast:
Jun '24 |
+/-
%
|
||
Revenue | 12 12 |
74%
74%
|
|
Gross Profit | 7.77 7.77 |
81%
81%
|
|
EBITDA | -187 -187 |
130%
130%
|
EBIT (Operating Income) EBIT | -191 -191 |
126%
126%
|
Net Profit | -154 -154 |
107%
107%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. The firm focuses on targeted therapeutics for patients selected using molecular diagnostics. Its product candidate, IDE196, is a protein kinase C inhibitor for genetically-defined cancers having GNAQ or GNA11 gene mutations. The company was founded by Yujiro S. Hata and Jeffrey Hager in June 2015 and is headquartered in South San Francisco, CA.
Head office | United States |
CEO | Yujiro Hata |
Employees | 124 |
Founded | 2015 |
Website | www.ideayabio.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.